Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT) - Takeaways - MDSpire

Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT)

  • By

  • Selim Corbacioglu

  • Rajinder Bajwa

  • Ali Bülent Antmen

  • Adriana Balduzzi

  • Jaap Jan Boelens

  • Francesca Bonifazi

  • Simone Cesaro

  • Fabio Ciceri

  • Antonio Colecchia

  • Fiona Dignan

  • Katharina Kleinschmidt

  • Kris M. Mahadeo

  • Antonio Pagliuca

  • Petr Sedlacek

  • Peter J. Shaw

  • Jerry Stein

  • Zofia Szmit

  • Francesco Tambaro

  • Elif Ince

  • Marta Verna

  • Akif Yesilipek

  • Marco Zecca

  • Paul G. Richardson

  • Mohamad Mohty

  • Krzysztof Kalwak

  • January 13, 2026

  • 0 min

Share

  • 1

    Sinusoidal Obstruction Syndrome (SOS/VOD) is a severe post-transplant complication in children, with incidence rates exceeding 15%.

  • 2

    Anicteric SOS/VOD occurs in up to 30% of pediatric patients, complicating diagnosis due to the lack of hyperbilirubinemia.

  • 3

    The European Society for Blood and Marrow Transplantation established pediatric-specific diagnostic criteria to improve SOS/VOD detection.

  • 4

    Defibrotide has shown promise in reducing endothelial damage and improving outcomes in pediatric patients at risk for SOS/VOD.

  • 5

    Diagnostic criteria significantly influence the reported incidence and severity of SOS/VOD, with the pEBMT criteria being more sensitive than previous standards.

Original Source(s)

Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT)

  • by Selim Corbacioglu, Rajinder Bajwa, Ali Bülent Antmen, Adriana Balduzzi, Jaap Jan Boelens, Francesca Bonifazi, Simone Cesaro, Fabio Ciceri, Antonio Colecchia, Fiona Dignan, Katharina Kleinschmidt, Kris M. Mahadeo, Antonio Pagliuca, Petr Sedlacek, Peter J. Shaw, Jerry Stein, Zofia Szmit, Francesco Tambaro, Elif Ince, Marta Verna, Akif Yesilipek, Marco Zecca, Paul G. Richardson, Mohamad Mohty, Krzysztof Kalwak

  • January 13, 2026

Related Content

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease

Gene- and subtype-dependent prognostic impact of ras pathway mutations in acute myeloid leukemia: a cohort study of 2,500 patients

Designing universal T cell therapies: strategies to evade natural killer cells